Martin P BÃ©hÃ©

List of Publications by Year
in descending order

Version: 2024-02-01

84	3,965	109321	128289
papers	citations	35 h-index	60 g-index

87	87	87	3717
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: Effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. Journal of Controlled Release, 2009, 138, 148-159.	9.9	173
2	Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 368-371.	2.1	159
3	First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible. Journal of Nuclear Medicine, 2011, 52, 1412-1417.	5.0	157
4	Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes and Endocrinology,the, 2013, 1, 115-122.	11.4	153
5	Indication for Different Mechanisms of Kidney Uptake of Radiolabeled Peptides. Journal of Nuclear Medicine, 2007, 48, 596-601.	5.0	150
6	Exendin-4â€“Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT. Journal of Nuclear Medicine, 2010, 51, 1059-1067.	5.0	141
7	Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Seminars in Nuclear Medicine, 2002, 32, 97-109.	4.6	131
8	Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin. Diabetologia, 2014, 57, 950-959.	6.3	129
9	[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. Journal of Nuclear Medicine, 2006, 47, 2025-33.	5.0	123
10	Bioreversibly crosslinked polyplexes of PEI and high molecular weight PEG show extended circulation times in vivo. Journal of Controlled Release, 2007, 124, 69-80.	9.9	110
11	Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. , 1998, 75, 406-411.		109
12	Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 424-430.	6.4	99
13	Crosslinked nanocarriers based upon poly(ethylene imine) for systemic plasmid delivery: In vitro characterization and in vivo studies in mice. Journal of Controlled Release, 2007, 118, 370-380.	9.9	98
14	In Vivo SPECT and Real-Time Gamma Camera Imaging of Biodistribution and Pharmacokinetics of siRNA Delivery Using an Optimized Radiolabeling and Purification Procedure. Bioconjugate Chemistry, 2009, 20, 174-182.	3.6	97
15	Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 597-606.	6.4	95
16	[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptorâ€“Targeted Therapy for Insulinoma. Clinical Cancer Research, 2007, 13, 3696-3705.	7.0	92
17	Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1868-1877.	6.4	87
18	Noninvasive positron emission tomography and fluorescence imaging of CD133+tumor stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E692-E701.	7.1	83

#	Article	IF	Citations
19	A new technique for in vivo imaging of specific GLP-1 binding sites: First results in small rodents. Regulatory Peptides, 2006, 137, 162-167.	1.9	77
20	Inflammatory neovascularization during graft-versus-host disease is regulated by Î±v integrin and miR-100. Blood, 2013, 121, 3307-3318.	1.4	75
21	CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. Journal of Nuclear Medicine, 2005, 46, 1727-36.	5.0	72
22	Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1140-1146.	6.4	67
23	Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?. Journal of Nuclear Medicine, 2005, 46, 1561-9.	5.0	66
24	Trastuzumabâˆ’Polyethylenimineâˆ’Polyethylene Glycol Conjugates for Targeting Her2-Expressing Tumors. Bioconjugate Chemistry, 2006, 17, 1190-1199.	3.6	64
25	Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. Journal of Nuclear Medicine, 2005, 46, 1012-5.	5.0	63
26	Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocrine-Related Cancer, 2006, 13, 1203-1211.	3.1	55
27	64Cu- and 68Ga-Labelled [Nle14,Lys40(Ahx-NODAGA)NH2]-Exendin-4 for Pancreatic Beta Cell Imaging in Rats. Molecular Imaging and Biology, 2014, 16, 255-263.	2.6	55
28	Exendinâ€4 analogs in insulinoma theranostics. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 656-672.	1.0	54
29	Cholecystokinin 2 Receptor Agonist ¹⁷⁷Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. Journal of Nuclear Medicine, 2020, 61, 520-526.	5.0	53
30	Dual, Siteâ€Specific Modification of Antibodies by Using Solidâ€Phase Immobilized Microbial Transglutaminase. ChemBioChem, 2017, 18, 1923-1927.	2.6	51
31	18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nuclear Medicine Communications, 2004, 25, 439-443.	1.1	50
32	Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy. Cellular Signalling, 2016, 28, 1412-1421.	3.6	48
33	Guidance on current good radiopharmacy practice for the smallâ€scale preparation of radiopharmaceuticals using automated modules: a European perspective. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 615-620.	1.0	44
34	Two Technetium-99m-Labeled Cholecystokinin-8 (CCK8) Peptides for Scintigraphic Imaging of CCK Receptors. Bioconjugate Chemistry, 2004, 15, 561-568.	3.6	43
35	Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog ¹⁷⁷Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?. Journal of Nuclear Medicine, 2019, 60, 393-399.	5.0	42
36	Non-Invasive In Vivo Imaging of Tumor-Associated CD133/Prominin. PLoS ONE, 2010, 5, e15605.	2.5	36

#	Article	IF	Citations
37	Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Research, 2003, 63, 1333-8.	0.9	35
38	Targets and probes for non-invasive imaging of Î²-cells. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 712-727.	6.4	32
39	A comparison of three 67/68Ga-labelled exendin-4 derivatives for Î²-cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelator. EJNMMI Research, 2014, 4, 31.	2.5	31
40	Novel peptide probes to assess the tensional state of fibronectin fibers in cancer. Nature Communications, 2017, 8, 1793.	12.8	31
41	Correlation of Red Marrow Radiation Dosimetry with Myelotoxicity: Empirical Factors Influencing the Radiation-Induced Myelotoxicity of Radiolabeled Antibodies, Fragments and Peptides in Pre-Clinical and Clinical Settings. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 445-464.	1.0	30
42	Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neuroscience Letters, 2009, 449, 240-245.	2.1	30
43	GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs. European Journal of Endocrinology, 2005, 153, 605-612.	3.7	29
44	Influence of Somatostatin Receptor Scintigraphy and CT/MRI on the Clinical Management of Patients with Gastrointestinal Neuroendocrine Tumors: An Analysis in 188 Patients. Digestion, 2003, 68, 80-85.	2.3	27
45	Activated Platelets in Carotid Artery Thrombosis in Mice Can Be Selectively Targeted with a Radiolabeled Single-Chain Antibody. PLoS ONE, 2011, 6, e18446.	2.5	24
46	Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins. Journal of Controlled Release, 2019, 307, 379-392.	9.9	22
47	Multifactorial diagnostic NIR imaging of CCK2R expressing tumors. Biomaterials, 2013, 34, 5172-5180.	11.4	21
48	Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients. Journal of Nuclear Medicine, 2019, 60, 812-816.	5.0	21
49	Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting. Journal of Medicinal Chemistry, 2020, 63, 4484-4495.	6.4	20
50	Design of Radiolabeled Analogs of Minigastrin by Multiple Amide-to-Triazole Substitutions. Journal of Medicinal Chemistry, 2020, 63, 4496-4505.	6.4	20
51	Evaluation of Â¹Â¹Â¹In-Labelled Exendin-4 Derivatives Containing Different Meprin Î²-Specific Cleavable Linkers. PLoS ONE, 2015, 10, e0123443.	2.5	20
52	Fibronectin fibers are highly tensed in healthy organs in contrast to tumors and virus-infected lymph nodes. Matrix Biology Plus, 2020, 8, 100046.	3.5	19
53	Evaluation of Actinium-225 Labeled Minigastrin Analogue [225Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy. Pharmaceutics, 2020, 12, 1088.	4.5	19
54	Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting. Molecular Pharmaceutics, 2019, 16, 3760-3769.	4.6	17

#	Article	IF	Citations
55	Lokalisation von Gastrinomen mit nuklearmedizinischen Methoden. Wiener Klinische Wochenschrift, 2007, 119, 593-596.	1.9	16
56	HER2 Targeted Polyplexes: The Effect of Polyplex Composition and Conjugation Chemistry on in Vitro and in Vivo Characteristics. Bioconjugate Chemistry, 2008, 19, 244-253.	3.6	16
57	In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. In Vivo, 2011, 25, 55-9.	1.3	16
58	Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [¹⁷⁷Lu]Lu-PP-F11N. Theranostics, 2020, 10, 10861-10873.	10.0	15
59	Biodistribution, Blood Half-Life, and Receptor Binding of a Somatostatin-Dextran Conjugate. Medical Oncology, 2001, 18, 59-64.	2.5	14
60	Biodistribution of Site-Specific PEGylated Fibroblast Growth Factor-2. ACS Biomaterials Science and Engineering, 2020, 6, 425-432.	5.2	13
61	1,5-Disubstituted 1,2,3-Triazoles as Amide Bond Isosteres Yield Novel Tumor-Targeting Minigastrin Analogs. ACS Medicinal Chemistry Letters, 2021, 12, 585-592.	2.8	13
62	Optical Imaging of CCK2/Gastrin Receptor-Positive Tumors With a Minigastrin Near-Infrared Probe. Investigative Radiology, 2011, 46, 196-201.	6.2	12
63	Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry. NeuroImage, 2013, 79, 191-200.	4.2	12
64	Self-assembled gold coating enhances X-ray imaging of alginate microcapsules. Nanoscale, 2015, 7, 2480-2488.	5.6	12
65	Elucidating the Structureâ€“Activity Relationship of the Pentaglutamic Acid Sequence of Minigastrin with Cholecystokinin Receptor Subtype 2. Bioconjugate Chemistry, 2019, 30, 657-666.	3.6	12
66	Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates. Journal of Peptide Science, 2017, 23, 38-44.	1.4	11
67	Radiosynthesis and evaluation of an 18Fâ€“labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma. EJNMMI Radiopharmacy and Chemistry, 2018, 3, 1.	3.9	11
68	Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats. Anticancer Research, 2007, 27, 907-12.	1.1	11
69	EANM guideline on quality risk management for radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3353-3364.	6.4	11
70	Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 9.	3.9	10
71	Imaging Lung Tumors with Peptide-Based Radioligands. Clinical Lung Cancer, 2003, 5, 119-124.	2.6	9
72	New Insights into Arrestin Recruitment to GPCRs. International Journal of Molecular Sciences, 2020, 21, 4949.	4.1	9

#	Article	IF	Citations
73	A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression. Cancer Immunology Research, 2022, 10, 626-640.	3.4	9
74	Enhanced Specific Activity by Multichelation of Exendin-3 Leads To Improved Image Quality and In Vivo Beta Cell Imaging. Molecular Pharmaceutics, 2018, 15, 486-494.	4.6	8
75	Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin 177Lu-PP-F11N. Cancers, 2021, 13, 2629.	3.7	8
76	Distance-Dependent Cellular Uptake of Oligoproline-Based Homobivalent Ligands Targeting GPCRsâ€"An Experimental and Computational Analysis. Bioconjugate Chemistry, 2020, 31, 2431-2438.	3.6	5
77	Targeted Radiotherapeutics from 'Bench-to-Bedside'. Chimia, 2022, 74, 939.	0.6	5
78	Exploring the signaling space of a GPCR using bivalent ligands with a rigid oligoproline backbone. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	5
79	Radiolabeled ¹¹¹In-FGF-2 Is Suitable for In Vitro/Ex Vivo Evaluations and In Vivo Imaging. Molecular Pharmaceutics, 2017, 14, 639-648.	4.6	4
80	Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [177Lu]Lu-PP-F11N. Pharmaceutics, 2021, 13, 2156.	4.5	4
81	Scintigraphic assessment of salivary gland function in a rat model. In Vivo, 2010, 24, 681-5.	1.3	3
82	Radioimmunotherapy versus traditional, nontargeted forms of systemic cancer treatment. Expert Review of Anticancer Therapy, 2001, 1, 501-505.	2.4	1
83	Distribution, Elimination, and Renal Handling of ^{99m}Technetium-Demogastrin 1. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 169-174.	1.0	1
84	Prostate cancer imaging and therapy. , 2018, , .		0